LAUSR

Dovitinib enhances temozolomide efficacy in glioblastoma cells

Sign Up to like & get
recommendations!
0 Published in 2017 at "Molecular Oncology"

DOI: 10.1002/1878-0261.12076

Abstract: The multikinase inhibitor and FDA‐approved drug dovitinib (Dov) crosses the blood–brain barrier and was recently used as single drug application in clinical trials for GB patients with recurrent disease. The Dov‐mediated molecular mechanisms in GB… read more here.

Keywords: enhances temozolomide; treatment; dov; dovitinib enhances ... See more keywords